SBH
ADMA icon

Segall Bryant & Hamill’s ADMA Biologics ADMA Stock Holding History

Segall Bryant & Hamill’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,280
Closed -$219K – 593
2026
Q1 		$219K Hold
24,280
– – ﹤0.01% 576
2025
Q4 		$443K Sell
24,280
-187,887
-89% -$3.17M 0.01% 556
2025
Q3 		$3.11M Sell
212,167
-65,566
-24% -$1.12M 0.04% 362
2025
Q2 		$5.06M Sell
277,733
-18,709
-6% -$382K 0.07% 313
2025
Q1 		$5.88M Sell
296,442
-9,910
-3% -$171K 0.09% 287
2024
Q4 		$5.25M Sell
306,352
-44,987
-13% -$846K 0.07% 325
2024
Q3 		$7.02M Sell
351,339
-99,936
-22% -$1.55M 0.1% 281
2024
Q2 		$5.05M Buy
+451,275
New +$3.79M 0.09% 293

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Segall Bryant & Hamill's ADMA Position: Q2 2026 in Review

Segall Bryant & Hamill sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 24,280 shares — an estimated $219K sold.

Segall Bryant & Hamill first reported a position in ADMA in Q2 2024 and held it in 8 quarters. The position peaked at $7.02M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Segall Bryant & Hamill reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Segall Bryant & Hamill sold 24,280 ADMA Biologics shares in Q2 2026, an estimated $219K.
  • Segall Bryant & Hamill first reported a position in ADMA Biologics in Q2 2024 and held it in 8 quarters.
  • Segall Bryant & Hamill's ADMA Biologics position peaked at $7.02M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.